report_id=VIT669 What factors are influencing the growth of the 23 Valent Pneumococcal Polysaccharide Vaccine Market over the forecast period? What is the competitive landscape in Vietnam 23 Valent ...

The downside comes after PCVX reports mixed results from a mid-stage study on its pneumococcal vaccine in infants.

Vaxcyte is awaiting data from another vaccine candidate for invasive pneumococcal disease (IPD) before advancing to Phase III.

The last time I spoke about Vaxcyte, Inc. (NASDAQ:PCVX) it was in a Seeking Alpha article entitled "Vaxcyte: End Of Phase 2 Meeting FDA Q4 Of 2023 To Get Ball Rolling." With respect to this ...

Supporting Platform’s Potential to Deliver Broadest-Spectrum Infant Pneumococcal Conjugate Vaccine (PCV) Candidates -- -- Company Selects VAX-24 Mid Dose (2.2mcg) as Basis for Optimized Dose ...

VAX-24 Mid dose met Phase 2 non-inferiority criteria for 20 of 24 serotypes and showed strong immune responses across all doses. Full post-dose 4 booster data is expected by late 2025, with a ...

today shared positive topline results from its Phase 2 dose-finding study evaluating the safety, tolerability and immunogenicity of VAX-24, the Company’s 24-valent pneumococcal conjugate vaccine ...

Supporting Platform’s Potential to Deliver Broadest-Spectrum Infant Pneumococcal Conjugate Vaccine (PCV) Candidates -- -- Company Selects VAX-24 Mid Dose (2.2mcg) as Basis for Optimized Dose ...

The vaccine is administered as a single dose. MSD Research Laboratories Global Clinical ... that have been responsible for an increasing proportion of adult invasive pneumococcal disease cases, ...

CAPVAXIVE is specifically tailored to address the serotypes predominantly responsible for adult IPD, including eight unique serotypes not covered by other pneumococcal vaccines. It is administered as ...